Evidence map›Paper›PMID 26270813›Full record

ArticlePloS one2015

Mu Opioid Splice Variant MOR-1K Contributes to the Development of Opioid-Induced Hyperalgesia.

Folabomi A Oladosu, Matthew S Conrad, Sandra C O'Buckley, Naim U Rashid, Gary D Slade, Andrea G Nackley

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Interactive effects of morphine and the HIV integrase inhibitor, cabotegravir, in male and female mice.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025
    Article
  4. Opioid-Induced Hyperalgesia and Tolerance Are Driven by HCN Ion Channels.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  5. Opioid-induced Neurotoxicity in Patients with Cancer Pain.Current treatment options in oncology · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Epigenetic regulation in opioid induced hyperalgesia.Neurobiology of pain (Cambridge, Mass.)
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Folabomi A OladosuCenter of Pain Research and Innovation, University of North Carolina-Chapel Hill, Chapel Hill, NC, United States of America.
Matthew S ConradNeuroscience Program, University of Illinois at Urbana-Champaign, Urbana, IL, United States of America.
Sandra C O'BuckleyCenter of Pain Research and Innovation, University of North Carolina-Chapel Hill, Chapel Hill, NC, United States of America.
Naim U RashidDepartment of Biostatistics, University of North Carolina-Chapel Hill, Chapel Hill, NC United States of America.
Gary D SladeCenter of Pain Research and Innovation, University of North Carolina-Chapel Hill, Chapel Hill, NC, United States of America.
Andrea G NackleyCenter of Pain Research and Innovation, University of North Carolina-Chapel Hill, Chapel Hill, NC, United States of America.
University of North Carolina at Chapel Hill · USUniversity of Illinois Urbana-Champaign · US

Funding

Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
North Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9M
Vulvar Vestibulitis syndrome (VVS)P01NS045685 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ESSICK, GREGORY KENT · 2004 to 2014
$12.5M
Persistent COMT-dependent Pain: Role of beta-adrenergic ReceptorsR01NS072205 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NACKLEY, ANDREA G · 2011 to 2014
$1.4M
NCATS NIH HHS UL1 TR001111NCATS NIH HHS UL1 TR002489NINDS NIH HHS P01 NS045685NINDS NIH HHS R01 NS072205
6 · The paper itself

Abstract

backgroundA subset of the population receiving opioids for the treatment of acute and chronic clinical pain develops a paradoxical increase in pain sensitivity known as opioid-induced hyperalgesia. Given that opioid analgesics are one of few treatments available against clinical pain, it is critical to determine the key molecular mechanisms that drive opioid-induced hyperalgesia in order to reduce its prevalence. Recent evidence implicates a splice variant of the mu opioid receptor known as MOR-1K in the emergence of opioid-induced hyperalgesia. Results from human genetic association and cell signaling studies demonstrate that MOR-1K contributes to decreased opioid analgesic responses and produces increased cellular activity via Gs signaling. Here, we conducted the first study to directly test the role of MOR-1K in opioid-induced hyperalgesia. METHODS AND

resultsIn order to examine the role of MOR-1K in opioid-induced hyperalgesia, we first assessed pain responses to mechanical and thermal stimuli prior to, during, and following chronic morphine administration. Results show that genetically diverse mouse strains (C57BL/6J, 129S6, and CXB7/ByJ) exhibited different morphine response profiles with corresponding changes in MOR-1K gene expression patterns. The 129S6 mice exhibited an analgesic response correlating to a measured decrease in MOR-1K gene expression levels, while CXB7/ByJ mice exhibited a hyperalgesic response correlating to a measured increase in MOR-1K gene expression levels. Furthermore, knockdown of MOR-1K in CXB7/ByJ mice via chronic intrathecal siRNA administration not only prevented the development of opioid-induced hyperalgesia, but also unmasked morphine analgesia.

conclusionsThese findings suggest that MOR-1K is likely a necessary contributor to the development of opioid-induced hyperalgesia. With further research, MOR-1K could be exploited as a target for antagonists that reduce or prevent opioid-induced hyperalgesia.

Indexed as

Alternative SplicingAnalgesics, OpioidAnimalsDisease Models, AnimalFemaleGene Expression RegulationGenetic VariationHumansHyperalgesiaMaleMiceMorphineReceptors, Opioid, muAnalgesics, OpioidMorphineOprm protein, mouseReceptors, Opioid, mu

Identifiers

PMID26270813
PMCPMC4535978
OpenAlexW2097904425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.